Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018

SELL
$18.04 - $26.41 $4.73 Million - $6.93 Million
-262,400 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$21.38 - $29.68 $1.55 Million - $2.15 Million
-72,280 Reduced 21.6%
262,400 $6 Million
Q1 2018

May 15, 2018

SELL
$21.76 - $34.22 $1.83 Million - $2.87 Million
-84,000 Reduced 20.06%
334,680 $0
Q4 2017

Feb 14, 2018

BUY
$19.0 - $23.09 $691,771 - $840,683
36,409 Added 9.52%
418,680 $8.84 Million
Q3 2017

Nov 14, 2017

BUY
$13.53 - $18.17 $5.17 Million - $6.95 Million
382,271
382,271 $6.95 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $55.4M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.